Biotech Values

[DewDiligence]

Re: ENTA’s cash balance and liquidity

http://finance.yahoo.com/news/enanta-pharmaceuticals-reports-financial-results-113000669.html

ENTA’s cash balance at 6/30/14 was $137.6M, an increase of about $36M relative to the 3/31/14 balance thanks to the $40M in milestone payments received from ABBV for the 3-DAA submission in the US and EU.

Adding in the expected $150M in milestone payments from ABBV for FDA and EMA approval of the 3-DAA HCV regimen (#msg-100940717), and the likelihood of a $15M milestone payment from NVS for starting a phase-2b trial of EDP-239 (#msg-105063800), absent a glitch ENTA could soon be rolling in almost $300M of cash.